ClinicalTrials.gg
CompletedNCT05001737EMERALDUpdated Aug 26, 2026Results posted

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

A Phase 3 interventional study of Emapalumab in Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis and Still Disease, sponsored by Swedish Orphan Biovitrum. Completed at 44 sites in 13 countries. Open to participants aged 6 Months to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Swedish Orphan Biovitrum · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
6 Months to 80 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.

Read the detailed description

Study NI-0501-14 is a two-cohort trial that enrolls subjects who are diagnosed with sHLH/MAS (MAS being a form of secondary HLH) and who are presenting an inadequate response to high doses of GCs. These subjects will be enrolled in 2 cohorts as per their background disease. The cohorts are defined as follows:

  • Cohort 1: MAS in the context of sJIA and AOSD.
  • Cohort 2: MAS in the context of pediatric and adult SLE.

The study has the objectives to investigate the efficacy, safety and tolerability, for 8 weeks, and PK and PD, QoL and immunogenicity in these 2 cohorts for up to 1 year after last dose of of emapalumab.

Macrophage Activation Syndrome (MAS) Secondary Hemophagocytic Lymphohistiocytosis (sHLH) systemic Juvenile Idiopathic Arthritis (sJIA) Adult-onset Still's Disease (AOSD) Systemic Lupus Erythematosus (SLE)

02

Conditions studied

  • Macrophage Activation Syndrome
  • Secondary Hemophagocytic Lymphohistiocytosis
  • Still Disease
  • Systemic Lupus Erythematosus
  • SJIA
  • AOSD
  • MAS
03

In context

Macrophage Activation Syndrome

20 studies on the registry are indexed under Macrophage Activation Syndrome; 4 are open to participants now.

This study's enrollment of 33 is close to the median of 33 across 11 interventional studies indexed under Macrophage Activation Syndrome.

Browse Macrophage Activation Syndrome studies →

Lead sponsor

Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. provided by the subject or by the subject s' legally authorized representative(s) with the assent of subjects who are legally capable of providing it, as required by local law.
  2. Male and female subjects aged between 6 months and 80 years of age at the time of diagnosis of MAS.
  3. MAS defined as per the criteria defined below for each cohort and requiring treatment with GCs.

Interventional phase in all cohorts

  1. Informed consent provided by the subject or by the subject's legally authorized representative(s) with the assent of subjects who are legally capable of providing it, as as required by local law.
  2. Male and female subjects aged between 6 months and 80 years of age at the time of diagnosis of active MAS.
  3. Subjects who have shown an inadequate response to high dose intravenous (i.v.) GCs administered for at least 3 days according to local standard clinical practice, including but not limited to pulses of 30 mg/kg PDN on 3 consecutive days. High i.v. GCs dose is recommended not to be lower than 2 mg/kg/ day PDN equivalent (or at least 60 mg/day in pediatric subjects of 30 kg or more, and at least 1g/day in adult MAS subjects). In case of rapid worsening of the subject's condition and/or laboratory parameters, as per Investigator judgment, inclusion may occur within less than 3 days from starting high dose GCs.
  4. Diagnosis of active MAS confirmed by the treating rheumatologist, having ascertained the followings:

    a. Febrile subjects presenting with ferritin > 684 ng/mL. b. and any 2 of: i. count ≤ 181 x109/L ii. -level > 48 U/L iii. Triglycerides > 156 mg/dL iv. Fibrinogen level ≤ 360 mg/dL

  5. Female subjects of willing to use highly effective methods of from study drug initiation to 6 months after the last dose of study drug.

    Specific inclusion criteria to Cohort 1 and Cohort 2

  6. Cohort 1:

    1. Confirmed sJIA diagnosis. For subjects presenting with MAS in the context of the onset of sJIA, high presumption of sJIA will suffice for eligibility.
    2. Confirmed diagnosis of AOSD as per Yamaguchi criteria.
  7. Cohort 2:

    1. Confirmed diagnosis of SLE as per SLICC'12 criteria.

Exclusion criteria

Exclusion criteria

  1. Primary HLH documented by either the presence of a known causative genetic mutation or abnormal perforin expression and CD107a degranulation assay as described with primary hemophagocytic lymphohistiocytosis or by the presence of family history.
  2. Confirmed . Note: subjects with a suspected malignancy should have mononuclear cells typed by flow cytometry and/or tissue , as applicable, to rule out malignancy.
  3. Treatment with canakinumab, JAK inhibitors, TNF inhibitors and tocilizumab at the time of emapalumab initiation.
  4. Ongoing treatment with anakinra at a dose above 4 mg/kg at time of emapalumab initiation.
  5. Subjects treated with etoposide for MAS in the last 1 month.
  6. Clinically active mycobacteria (typical and atypical), Histoplasma Capsulatum, or Salmonella infections.
  7. Evidence of leishmania infections.
  8. Evidence of latent tuberculosis.
  9. History of or allergy to any component of the study drug.
  10. Receipt of a Bacillus Calmette-Guerin (BCG) vaccine within 12 weeks prior to screening.
  11. Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screening.
  12. Pregnancy or lactating female subjects.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Cohort 1 (sJIA and AOSD) and Cohort 2 (SLE)

    MAS in the context of systemic juvenile idiopathic arthritis and adult onset Still's disease (sJIA and AOSD) or SLE

    Drug: Emapalumab

Interventions

  • Emapalumab iv infusion

    Also known as: NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO)

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab

    Resolution of clinical signs and symptoms present at baseline: The macrophage activation syndrome (MAS) clinical activity will be measured on a visual analog scale (VAS) 10 cm. Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm. Clinical signs will be considered as resolved if VAS is below or equal to 1/10. And Normalization of laboratory parameters relevant to MAS, as follows: WBC above LLN, platelet count above LLN, LDH below 1.5 ULN, ALT below 1.5 ULN, AST below 1.5 ULN, fibrinogen higher than 100 mg/dL, ferritin levels decreased by at least 80 % from values at screening or baseline (whichever is higher) or below 2000 ng/ml, whichever is lower

    Time frame: 8 weeks

Secondary outcomes

  1. Number of Patients With Glucocorticoids (GC)s Tapering to a Dose Below 50% of Prednisolone (PDN) Equivalent at the Time of Emapalumab Start or to the Same (or Lower) Dose Being Administered Before the Occurrence of MAS Whichever Occurs First

    GC tapering as per investigator discretion

    Time frame: At any time within the first 8 weeks from start of emapalumab treatment

  2. Number of Patients With GCs Tapering to ≤1mg/kg/Day of PDN Equivalent at Any Time Until End of Study (EOS).

    GC tapering as per investigator discretion

    Time frame: At any time in the study, up to 1 year

  3. Time to Achieve GCs Tapering

    Median time to achieve GCs tapering to a dose \< 50 % of PDN equivalent at the time of emapalumab start or to the same (or lower) dose being administered before the occurrence of MAS (in patients already treated for the underlying condition), or to ≤1mg/kg/Day of PDN Equivalent, whichever occurs first at any time during the study GC tapering as per investigator discretion

    Time frame: At any time in the study, up to 1 year

  4. Time to First Complete Response (CR)

    Time to CR until EOS Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity was measured on a visual analog scale (VAS) 10 cm. Definition of CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower.

    Time frame: At any time in the study, up to 1 year

  5. Proportion of Subjects With Overall Response as Defined by CR or Partial Response (PR)

    Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity was measured on a visual analog scale (VAS) 10 cm. CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower. PR: Resolution or improvement in clinical signs and symptoms measured by the MAS clinical activity on the VAS. The patient was classified as PR if he or she presented a VAS \<4/10. and Normalization of at least 3 of the abnormal baseline laboratory parameters relevant to MAS, as defined above.

    Time frame: At week 8

  6. Time to First Overall Response as Defined by CR or PR

    Time to first overall response CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower. PR: Resolution or improvement in clinical signs and symptoms measured by the MAS clinical activity on the VAS. The patient was classified as PR if he or she presented a VAS \<4/10. and Normalization of at least 3 of the abnormal baseline laboratory parameters relevant to MAS, as defined above.

    Time frame: At any time in the study, up to 1 year

  7. MAS Recurrence at Anytime After Achievement of CR

    Number of patients with MAS recurrence at anytime after achievement of CR

    Time frame: At any time after CR, up to 1 year

  8. Withdrawal From the Study Due to Lack of Response

    Number of patients withdrawn from the study due to lack of response as per Investigator decision

    Time frame: At any time in the study, up to 1 year

  9. Survival

    Number of patients alive at the end of study

    Time frame: At end of study, 1 year

Other outcomes

  1. Adverse Events (AEs) (Serious and Non-serious).

    number of patients that experienced at least one AE (serious and non-serious).

    Time frame: At any time in the study, up to 1 year

  2. Study Interruption Due to Safety Reasons

    Number of participants withdrawn from study treatment due to adverse event

    Time frame: At any time in the study, up to 1 year

  3. Laboratory Parameters

    Number of patients with clinically meaningful changes in hematology and chemistry laboratory parameters from baseline

    Time frame: At any time in the study, up to 1 year

  4. Patient Reported Outcomes : PedsQL™;

    Pediatric Quality of Life Inventory (PedsQL™; Generic Core Scales and Infant Scales, Acute versions) The PedsQL is scored on a 5-point Likert scale from: 0 (Never) to 4 (Almost always) Then, for ease of interpretability, items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life). To reverse score, transform the 0-4 scale items to 0-100 as follows: 0=100, 1=75, 2=50, 3=25, 4=0 To create the Total Scale Score, the mean is computed as the sum of all the items over the number of items answered on all the Scales (this also accounts for missing data). If more than 50% of the items in the scale are missing, the Scale Scores should not be computed. If 50% or more items are completed: Impute the mean of the completed items in a scale

    Time frame: Baseline, week 8, 6 months, and EOS (1 year)

  5. Patient Reported Outcomes: Clinician Global Impression of Severity

    Health-related quality of life: Global Assessment: Clinician Global Impression of Severity Number of patients having an overall severity of the health status over the past week assessed by the clinician as None, Mild, Moderate, or Severe, at the specified timepoints.

    Time frame: Baseline, Week 8, month 6 and EOS (1 year)

  6. Patient Reported Outcomes: Patient/Parent Global Impression of Severity

    Health-related quality of life: Global Assessment: Patient/Parent Global Impression of Severity Number of patients having an overall severity of the health status over the past week assessed by the Patient/Parent as None, Mild, Moderate, or Severe, at the specified timepoints.

    Time frame: Screening, Week 8, month 6 and EOS (1 year)

  7. PK Endpoints

    Serum concentrations of emapalumab vs. time

    Time frame: Baseline (Day 1), week 8, Day 60, Day 100, 6 Months, EOS (1 year)

  8. PD Endpoints Per Cohort: Chemokines

    Levels of the main IFN-γ-induced chemokine (CXCL9).

    Time frame: Baseline, week 8, 6 months, EOS (1 year)

  9. PD Endpoints Per Cohort: sCD25)

    Levels of MAS markers; sCD25 (Soluble CD25 (i.e., soluble IL-2 receptor))

    Time frame: Baseline, week 8, 6 months, EOS (1 year)

  10. Immunogenicity Endpoints

    Occurrence of ADAs to emapalumab until EOS (1 year after last dose of emapalumab) Baseline and overall incidence

    Time frame: At any time in the study, up to 1 year

07

Results

Posted Feb 19, 2026
Limitations and caveats
Enrollment in Cohort 2 was discontinued by the Sponsor after 8 (of 16 planned) patients were enrolled in June 2024 due to enrollment challenges in this patient population.

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Started258
Completed237
Not completed21

Outcome measures

PrimaryProportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab

Resolution of clinical signs and symptoms present at baseline: The macrophage activation syndrome (MAS) clinical activity will be measured on a visual analog scale (VAS) 10 cm. Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm. Clinical signs will be considered as resolved if VAS is below or equal to 1/10. And Normalization of laboratory parameters relevant to MAS, as follows: WBC above LLN, platelet count above LLN, LDH below 1.5 ULN, ALT below 1.5 ULN, AST below 1.5 ULN, fibrinogen higher than 100 mg/dL, ferritin levels decreased by at least 80 % from values at screening or baseline (whichever is higher) or below 2000 ng/ml, whichever is lower

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab114
SecondaryNumber of Patients With Glucocorticoids (GC)s Tapering to a Dose Below 50% of Prednisolone (PDN) Equivalent at the Time of Emapalumab Start or to the Same (or Lower) Dose Being Administered Before the Occurrence of MAS Whichever Occurs First

GC tapering as per investigator discretion

Time frame:
At any time within the first 8 weeks from start of emapalumab treatment
Reported as:
Count of participants · Participants
Number of Patients With Glucocorticoids (GC)s Tapering to a Dose Below 50% of Prednisolone (PDN) Equivalent at the Time of Emapalumab Start or to the Same (or Lower) Dose Being Administered Before the Occurrence of MAS Whichever Occurs First
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Number of Patients With Glucocorticoids (GC)s Tapering to a Dose Below 50% of Prednisolone (PDN) Equivalent at the Time of Emapalumab Start or to the Same (or Lower) Dose Being Administered Before the Occurrence of MAS Whichever Occurs First157
SecondaryNumber of Patients With GCs Tapering to ≤1mg/kg/Day of PDN Equivalent at Any Time Until End of Study (EOS).

GC tapering as per investigator discretion

Time frame:
At any time in the study, up to 1 year
Reported as:
Count of participants · Participants
Number of Patients With GCs Tapering to ≤1mg/kg/Day of PDN Equivalent at Any Time Until End of Study (EOS).
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Number of Patients With GCs Tapering to ≤1mg/kg/Day of PDN Equivalent at Any Time Until End of Study (EOS).196
SecondaryTime to Achieve GCs Tapering

Median time to achieve GCs tapering to a dose \< 50 % of PDN equivalent at the time of emapalumab start or to the same (or lower) dose being administered before the occurrence of MAS (in patients already treated for the underlying condition), or to ≤1mg/kg/Day of PDN Equivalent, whichever occurs first at any time during the study GC tapering as per investigator discretion

Time frame:
At any time in the study, up to 1 year
Reported as:
Median · weeks
Time to Achieve GCs Tapering
weeksCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Time to Achieve GCs Tapering5 (2.0 to 10.0)1 (1.0 to 5.0)
SecondaryTime to First Complete Response (CR)

Time to CR until EOS Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity was measured on a visual analog scale (VAS) 10 cm. Definition of CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower.

Time frame:
At any time in the study, up to 1 year
Reported as:
Median · weeks
Time to First Complete Response (CR)
weeksCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Time to First Complete Response (CR)8.4 (5.0 to 20.9)5.9 (3.4 to NA)
SecondaryProportion of Subjects With Overall Response as Defined by CR or Partial Response (PR)

Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity was measured on a visual analog scale (VAS) 10 cm. CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower. PR: Resolution or improvement in clinical signs and symptoms measured by the MAS clinical activity on the VAS. The patient was classified as PR if he or she presented a VAS \<4/10. and Normalization of at least 3 of the abnormal baseline laboratory parameters relevant to MAS, as defined above.

Time frame:
At week 8
Reported as:
Count of participants · Participants
Proportion of Subjects With Overall Response as Defined by CR or Partial Response (PR)
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Proportion of Subjects With Overall Response as Defined by CR or Partial Response (PR)166
SecondaryTime to First Overall Response as Defined by CR or PR

Time to first overall response CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower. PR: Resolution or improvement in clinical signs and symptoms measured by the MAS clinical activity on the VAS. The patient was classified as PR if he or she presented a VAS \<4/10. and Normalization of at least 3 of the abnormal baseline laboratory parameters relevant to MAS, as defined above.

Time frame:
At any time in the study, up to 1 year
Reported as:
Median · weeks
Time to First Overall Response as Defined by CR or PR
weeksCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Time to First Overall Response as Defined by CR or PR2.9 (1.4 to 8.4)3.7 (0.6 to NA)
SecondaryMAS Recurrence at Anytime After Achievement of CR

Number of patients with MAS recurrence at anytime after achievement of CR

Time frame:
At any time after CR, up to 1 year
Reported as:
Count of participants · Participants
MAS Recurrence at Anytime After Achievement of CR
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
MAS Recurrence at Anytime After Achievement of CR41
SecondaryWithdrawal From the Study Due to Lack of Response

Number of patients withdrawn from the study due to lack of response as per Investigator decision

Time frame:
At any time in the study, up to 1 year
Reported as:
Count of participants · Participants
Withdrawal From the Study Due to Lack of Response
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Withdrawal From the Study Due to Lack of Response00
SecondarySurvival

Number of patients alive at the end of study

Time frame:
At end of study, 1 year
Reported as:
Count of participants · Participants
Survival
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Survival238
Other pre-specifiedAdverse Events (AEs) (Serious and Non-serious).

number of patients that experienced at least one AE (serious and non-serious).

Time frame:
At any time in the study, up to 1 year
Reported as:
Count of participants · Participants
Adverse Events (AEs) (Serious and Non-serious).
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Adverse Events (AEs) (Serious and Non-serious).248
Other pre-specifiedStudy Interruption Due to Safety Reasons

Number of participants withdrawn from study treatment due to adverse event

Time frame:
At any time in the study, up to 1 year
Reported as:
Count of participants · Participants
Study Interruption Due to Safety Reasons
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Study Interruption Due to Safety Reasons11
Other pre-specifiedLaboratory Parameters

Number of patients with clinically meaningful changes in hematology and chemistry laboratory parameters from baseline

Time frame:
At any time in the study, up to 1 year
Reported as:
Count of participants · Participants
Laboratory Parameters
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Laboratory Parameters00
Other pre-specifiedPatient Reported Outcomes : PedsQL™;

Pediatric Quality of Life Inventory (PedsQL™; Generic Core Scales and Infant Scales, Acute versions) The PedsQL is scored on a 5-point Likert scale from: 0 (Never) to 4 (Almost always) Then, for ease of interpretability, items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life). To reverse score, transform the 0-4 scale items to 0-100 as follows: 0=100, 1=75, 2=50, 3=25, 4=0 To create the Total Scale Score, the mean is computed as the sum of all the items over the number of items answered on all the Scales (this also accounts for missing data). If more than 50% of the items in the scale are missing, the Scale Scores should not be computed. If 50% or more items are completed: Impute the mean of the completed items in a scale

Time frame:
Baseline, week 8, 6 months, and EOS (1 year)
Reported as:
Mean · score on a scale
Patient Reported Outcomes : PedsQL™;
score on a scaleCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Baseline43.18 ± 21.48851.45 ± 25.955
Week 867.88 ± 21.61779.35 ± NA
6 months72.85 ± 16.65085.87 ± 16.909
EOS (1 year)80.79 ± 18.02097.83 ± NA
Other pre-specifiedPatient Reported Outcomes: Clinician Global Impression of Severity

Health-related quality of life: Global Assessment: Clinician Global Impression of Severity Number of patients having an overall severity of the health status over the past week assessed by the clinician as None, Mild, Moderate, or Severe, at the specified timepoints.

Time frame:
Baseline, Week 8, month 6 and EOS (1 year)
Reported as:
Count of participants · Participants
Patient Reported Outcomes: Clinician Global Impression of Severity
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Baseline — none00
Baseline — mild11
Baseline — moderate151
Baseline — severe96
Week 8 — none116
Week 8 — mild51
Week 8 — moderate30
Week 8 — severe00
Month 6 — none165
Month 6 — mild11
Month 6 — moderate00
Month 6 — severe00
EOS (1 year) — none174
EOS (1 year) — mild30
EOS (1 year) — moderate01
EOS (1 year) — severe00
Other pre-specifiedPatient Reported Outcomes: Patient/Parent Global Impression of Severity

Health-related quality of life: Global Assessment: Patient/Parent Global Impression of Severity Number of patients having an overall severity of the health status over the past week assessed by the Patient/Parent as None, Mild, Moderate, or Severe, at the specified timepoints.

Time frame:
Screening, Week 8, month 6 and EOS (1 year)
Reported as:
Count of participants · Participants
Patient Reported Outcomes: Patient/Parent Global Impression of Severity
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Baseline — none00
Baseline — mild11
Baseline — moderate151
Baseline — severe96
Week 8 — none116
Week 8 — mild51
Week 8 — moderate30
Week 8 — severe00
Month 6 — none165
Month 6 — mild11
Month 6 — moderate00
Month 6 — severe00
EOS (1 year) — none174
EOS (1 year) — mild30
EOS (1 year) — moderate01
EOS (1 year) — severe00
Other pre-specifiedPK Endpoints

Serum concentrations of emapalumab vs. time

Time frame:
Baseline (Day 1), week 8, Day 60, Day 100, 6 Months, EOS (1 year)
Reported as:
Mean · ng/mL
PK Endpoints
ng/mLCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Baseline (Day 1)112541.47 ± 43924.399167990.22 ± 77376.997
Week 8170691.64 ± 220467.04181457.69 ± 126004.837
Day 6044314.88 ± 59798.35419532.33 ± 23182.423
Day 10015807.32 ± 26206.2248596.18 ± 10611.686
6 Months2215.22 ± 4545.31460.33 ± 1281.8
EOS (1 year)889.11 ± 3921.26674817.54 ± 167195.974
Other pre-specifiedPD Endpoints Per Cohort: Chemokines

Levels of the main IFN-γ-induced chemokine (CXCL9).

Time frame:
Baseline, week 8, 6 months, EOS (1 year)
Reported as:
Mean · ng/L
PD Endpoints Per Cohort: Chemokines
ng/LCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Baseline21344.26 ± 79546.8372352.57 ± 3674.773
Week 896.43 ± 128.617134.70 ± 149.996
6 months1095.19 ± 2677.991183.74 ± 126.758
EOS (1 year)293.05 ± 441.078123.12 ± 62.820
Other pre-specifiedPD Endpoints Per Cohort: sCD25)

Levels of MAS markers; sCD25 (Soluble CD25 (i.e., soluble IL-2 receptor))

Time frame:
Baseline, week 8, 6 months, EOS (1 year)
Reported as:
Mean · ng/L
PD Endpoints Per Cohort: sCD25)
ng/LCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Baseline21287.45 ± 34921.5204893.50 ± 2113.562
Week 83915.58 ± 2251.4572336.40 ± 810.798
Month 63967.38 ± 4018.1223424.00 ± 1371.916
EOS (1 year)3456.40 ± 3630.8063515.40 ± 2809.668
Other pre-specifiedImmunogenicity Endpoints

Occurrence of ADAs to emapalumab until EOS (1 year after last dose of emapalumab) Baseline and overall incidence

Time frame:
At any time in the study, up to 1 year
Reported as:
Count of participants · Participants
Immunogenicity Endpoints
ParticipantsCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Baseline ADA00
overall ADA incidence50

Adverse events

Collected over From signature of informed consent (i.e. screening) until EOS (1 year). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (sJIA and AOSD)2/25 (8%)18/25 (72%)24/25 (96%)
Cohort 2 (SLE)0/8 (0%)4/8 (50%)8/8 (100%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Still's diseaseMusculoskeletal and connective tissue disorders6/250/8
PneumoniaInfections and infestations5/250/8
Condition aggravatedGeneral disorders4/251/8
Lupus nephritisRenal and urinary disorders0/251/8
Abscess limbInfections and infestations0/251/8
Prothrombin level decreasedInvestigations0/251/8
Cytomegalovirus infectionInfections and infestations2/250/8
Herpes ZosterInfections and infestations2/250/8
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders2/250/8
Multiple organ dysfunction syndromeGeneral disorders1/250/8
Most frequent other events
Showing 10 of 66
Most frequent other events
EventCohort 1 (sJIA and AOSD)Cohort 2 (SLE)
Upper respiratory tract infectionInfections and infestations1/253/8
Still's diseaseMusculoskeletal and connective tissue disorders8/250/8
AnaemiaBlood and lymphatic system disorders7/250/8
Cytomegalovirus infectionInfections and infestations3/252/8
SinusitisInfections and infestations2/252/8
Epstein-Barr virus infectionInfections and infestations0/252/8
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders0/252/8
RashSkin and subcutaneous tissue disorders3/252/8
ConstipationGastrointestinal disorders0/252/8
Lupus nephritisRenal and urinary disorders0/252/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1 (sJIA and AOSD)Cohort 2 (SLE)Total
<=18 years17421
Between 18 and 65 years8412
>=65 years000
Age, Continuous
Age, Continuous(years)Cohort 1 (sJIA and AOSD)Cohort 2 (SLE)Total
Mean15.8 ± 15.5414.6 ± 6.7815.5 ± 13.83
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (sJIA and AOSD)Cohort 2 (SLE)Total
Female21526
Male437
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 (sJIA and AOSD)Cohort 2 (SLE)Total
Hispanic or Latino011
Not Hispanic or Latino22729
Unknown or Not Reported303
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 (sJIA and AOSD)Cohort 2 (SLE)Total
American Indian or Alaska Native000
Asian448
Native Hawaiian or Other Pacific Islander000
Black or African American022
White18220
More than one race000
Unknown or Not Reported303
Region of Enrollment
Region of Enrollment(participants)Cohort 1 (sJIA and AOSD)Cohort 2 (SLE)Total
United States246
Czechia404
Japan202
United Kingdom202
Spain213
Canada112
Netherlands202
Belgium101
China123
Italy404
France202
Germany202
Body weight
Body weight(kg)Cohort 1 (sJIA and AOSD)Cohort 2 (SLE)Total
Mean44.48 ± 21.77749.46 ± 33.99045.69 ± 24.761
08

Study locations

44 sites
  • UAB Hospital
    Birmingham, Alabama 35233, United States
  • UCLA Health
    Los Angeles, California 90095, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30329, United States
  • University of Minnesota Masonic Children's Hospital
    Minneapolis, Minnesota 55455, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Nationwide Children's Hospital, Abigail Wexner Research Institute
    Columbus, Ohio 43205, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Universitair Ziekenhuis Leuven
    Leuven, Belgium
  • Alberta Children's Hospital
    Calgary, Canada
  • University of Calgary
    Calgary, Canada
  • Centre Hospitalier de l'Université de Montréal
    Montreal, Canada
  • Centre Hospitalier Universitaire Sainte-Justine
    Montreal, Canada
  • Hospital for sick children
    Toronto, Canada
  • Beijing Children's Hospital
    Beijing, China
  • Beijing Friendship Hospital
    Beijing, China
  • Children's Hospital of Fudan University
    Shanghai, China
  • Fakultní nemocnice Olomouc
    Olomouc, Czechia
  • Vseobecna Fakultni Nemocnice v Praze
    Prague, Czechia
  • Hôpital Claude Huriez
    Lille, France
  • Hôpital De La Conception
    Marseille, France
  • Hôpital Necker-Enfants Malades
    Paris, France
  • Hôpital Universitaire Pitié Salpêtrière
    Paris, France
  • Charité Universitätsmedizin
    Berlin, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, Germany
  • IRCCS G. Gaslini
    Genova, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, Italy
  • Ospedale Pediatrico Bambino Gesù
    Roma, Italy
  • IRCCS - Materno-Infantile Burlo Garofolo
    Trieste, Italy
  • St. Marianna University School of Medicine Hospital
    Kawasaki, Japan
  • Osaka Medical and Pharmaceutical University Hospital
    Takatsuki, Japan
  • Tokyo Medical and Dental University Hospital
    Tokyo, Japan
  • Yokohama City University Hospital
    Yokohama, Japan
  • UMC Utrecht
    Utrecht, Netherlands
  • Szpital Specjalistyczny im. J. Dietla w Krakowie
    Krakow, Poland
  • Wojewódzki Specjalistyczny Szpital Dziecięcy im. św. Ludwika w Krakowie
    Krakow, Poland
  • Ortopedyczno - Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
    Poznan, Poland
  • Hospital Sant Joan de Déu
    Barcelona, Spain
  • Hospital Universitario La Paz
    La Paz, Spain
  • Hospital Universitario
    La Paz, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, Spain
  • Great Ormond Street Hospital
    London, United Kingdom
  • Imperial College Healthcare NHS Trust
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jun 2024, 30 months.

Results were first posted in Feb 2026, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2021
First posted
Aug 12, 2021
StartActual
Dec 15, 2021
Primary completionActual
Jun 30, 2024
CompletionActual
Jun 4, 2025
Results first posted
Feb 19, 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05001737
Responsible party
Sponsor
First posted
Aug 12, 2021
Start date
Dec 15, 2021
Primary completion
Jun 30, 2024
Completion
Jun 4, 2025
Results posted
Feb 19, 2026
Last update
Aug 26, 2026

Study contacts

Medical Director, MD
study director · Swedish Orphan Biovitrum

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emapalumab

Start the discussion